Short Interest in CalciMedica, Inc. (NASDAQ:CALC) Drops By 6.6%

CalciMedica, Inc. (NASDAQ:CALC) was the recipient of a significant decrease in short interest in the month of December. As of December 31st, there was short interest totalling 61,300 shares, a decrease of 6.6% from the December 15th total of 65,600 shares. Currently, 0.9% of the company’s shares are short sold. Based on an average daily trading volume, of 59,400 shares, the days-to-cover ratio is presently 1.0 days.

Insider Buying and Selling

In related news, CEO A. Rachel Leheny purchased 20,000 shares of the business’s stock in a transaction on Friday, November 1st. The shares were bought at an average price of $3.75 per share, with a total value of $75,000.00. Following the completion of the purchase, the chief executive officer now directly owns 130,926 shares in the company, valued at approximately $490,972.50. This trade represents a 18.03 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Eric W. Roberts acquired 53,333 shares of the company’s stock in a transaction dated Friday, November 1st. The shares were purchased at an average price of $3.75 per share, with a total value of $199,998.75. Following the completion of the acquisition, the insider now owns 164,706 shares in the company, valued at approximately $617,647.50. The trade was a 47.89 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders have acquired 252,744 shares of company stock worth $942,510. 41.55% of the stock is owned by company insiders.

Institutional Trading of CalciMedica

Several large investors have recently added to or reduced their stakes in the stock. PVG Asset Management Corp acquired a new position in shares of CalciMedica during the third quarter worth about $67,000. Atria Investments Inc raised its holdings in shares of CalciMedica by 136.5% during the 3rd quarter. Atria Investments Inc now owns 26,503 shares of the company’s stock valued at $117,000 after buying an additional 15,296 shares during the period. Finally, Geode Capital Management LLC lifted its position in CalciMedica by 51.2% during the 3rd quarter. Geode Capital Management LLC now owns 66,553 shares of the company’s stock worth $295,000 after acquiring an additional 22,525 shares in the last quarter.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and set a $16.00 price target on shares of CalciMedica in a research note on Thursday, November 14th.

CalciMedica Stock Down 2.5 %

Shares of CalciMedica stock traded down $0.08 during trading hours on Friday, hitting $3.09. The company’s stock had a trading volume of 21,907 shares, compared to its average volume of 25,828. The business has a fifty day moving average of $3.13 and a 200 day moving average of $3.86. CalciMedica has a 1-year low of $2.05 and a 1-year high of $8.38. The company has a market capitalization of $41.65 million, a PE ratio of -2.86 and a beta of 1.22.

About CalciMedica

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.